Transfusion Associated Hyperkalemia in Pediatric Population: Prevalence, Risk Factors, Survival, Infusion Rate and RBC unit Features

Chisa Yamada[1], Maureen Edelson[2], Angela Lee[3], Nabiha Huq Saifee[4], Burak Bahar[5], Meghan Delaney[5]

[1] Department of Pathology
Division of Transfusion Medicine
University of Michigan

[2]Department of Pathology and Laboratory Medicine
Nemours/A.I. DuPont Hospital for Children

[3]Division of Anesthesiology, Pain and Perioperative Medicine
~~Pain and Perioperative Medicine~~
Children's National Hospital
George Washington School of Medicine & Health Sciences

[4] Department of Pathology and Laboratory Medicine
Division of Transfusion Medicine
Seattle Children's and University of Washington

[5]Division of Pathology & Laboratory Medicine
Children's National Hospital
George Washington School of Medicine & Health Sciences

Address for correspondence:
Chisa Yamada, M.D.
University of Michigan
Transfusion Medicine
Department of Pathology
1500 E. Medical Center Dr.
SPC 5054, UH2F225
Ann Arbor, MI 48109-5054
Tel: (734) 936-9428
Fax: (734) 763-9505
E-mail: yamadac@med.umich.edu

Reprint will not be available from the author.
I should like to mention here that I and all of my coauthors have read the AABB's policy on Conflict of Interest and none of us have any Conflicts of Interest or financial interests related to this manuscript.

Running head: PED Transfusion Associated Hyperkalemia

Abstract

Background: Hyperkalemia is a rare life-threatening complication of RBC transfusion. Stored RBCs leak intracellular potassium (K+) into the supernatant; irradiation potentiates the K+ leak. Since characteristics of patients and implicated RBCs have not been studied systematically, a multi-center study of transfusion associated hyperkalemia (TAH) in pediatric population was conducted through AABB Pediatric Transfusion Medicine Subsection. Study Design: Medical records of patients <18 years old were retrospectively queried for hyperkalemia occurrence during or ≤12 hours after the completion of RBC transfusion in one-year period. Collected data included patient demographics, diagnosis, medical history, timing of hyperkalemia and transfusion, mortality, and RBC unit characteristics. Results/Findings: A total of 3,777 patients received 19,649 RBC units during the study period in four facilities. TAH was found in 35 patients (0.93%) in 37 occurrences. The patient median age and weight were 1.28 years old and 9.80 Kg, respectively. All patients had multiple serious comorbidities. There were 79 RBC units transfused in the TAH events; 62% were irradiated and the median age of the units was 10 days. The median total RBC volume transfused ≤12 hours before TAH was 24% of patient estimated total blood volume, and the median infusion rate (IR) was19.6 ml/Kg/hour. Mortality rate within one-day after the TAH event was 20%. Conclusions: The prevalence of TAH in children was low, however, the one-day mortality rate was 20%. Patients with multiple comorbidities may be at higher risk for TAH. The IR was higher for patients that had TAH than the IR threshold for safe transfusion.

Background

Transfusion associated hyperkalemia (TAH) is a rare, but potentially life-threatening complication of red blood cell (RBC) transfusion that may lead to cardiac arrest due to arrhythmia and depressed cardiac contraction.[1,2] Stored RBCs leak intracellular potassium (K+) in the supernatant of the RBC units due to an inhibition of the membrane Na-K-ATPase pump in cold temperature, and gamma irradiation to prevent graft-versus-host disease potentiates the K+ leak. Although the supernatant mean K+ level in the RBC unit can climb to as high as 78.5 mmol/L in CPDA-1 RBC units (storage day 35)[3], 50.0 and 46.0 mmol/L in AS-1 and AS-3 RBC units respectively (storage day 42)[3], and 80.7 mmol/L in irradiated AS-1 RBC units (storage day 28 with irradiation day 26)[4], Strauss[5] states that 15 ml/Kg RBC transfusion over 5 hours would not cause hyperkalemia in neonates. Neonatal K+ levels were also not significantly affected by low volume of RBC transfusion at~~in~~ normal infusion rates[6-8] because total transfused K+ dose is small and does not exceed the normal physiologic amount of K+ intake required by the neonate. In order to prevent TAH, most transfusion services that care for neonatal and pediatric patients have established practices to select RBC units for large volume transfusion that have shorter storage age and that are irradiated close to the time of issue, and RBC units are sometimes washed with~~by~~ normal saline to remove supernatant. Those practices are based on the fact that older RBC units have higher K+ concentrations, and decided by each transfusion service.

Serious repercussions of TAH with or without cardiac arrest have been reported[9-18], raising the concerns for the risks of TAH from large-volume ~~of~~ transfusions with or without rapid infusion rate (IR) for pediatric patients, especially for infants.[19,20] Patients who are undergoing procedures such as cardiac surgeries using cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), RBC exchange (RBCEx) and liver

transplantations may receive large-volume ~~of~~ RBC transfusions rapidly, and may be at increased risk for TAH. Because fresher units may not be available and waiting time of 30 minutes or more for supernatant removal may be too long in emergencies, the possibility of transient hyperkalemia may not be eliminated.

Since the occurrence of TAH and characteristics of patients and implicated blood products in pediatric population have not been studied systematically, a multi-center retrospective study for TAH was conducted through the AABB Pediatric Transfusion Medicine Subsection to determine the prevalence of this adverse event, as well as the patient and RBC unit characteristics associated with laboratory confirmed TAH.

Study Design

Data collection

The medical records of patients who received RBC transfusion and were younger than 18 years old at the time of transfusion in a one-year period (9/1/15-8/31/16) were retrospectively queried for hyperkalemia occurrence in four facilities (all children's hospitals in large academic medical facilities in the US) after local IRB approvals were obtained. TAH was defined as K+ levels above the institutional reference range (upper limit of 4.9-5.5 mmol/L depending on the patient's age and facility) during or within 12 hours after completions of RBC transfusion(s). Patients with minor K+ increase defined as $\leq$ 0.2 mmol/L between the prior K+ level and K+ level at the time of hyperkalemia occurrence were excluded as an acceptable variable even if K+ level increased to above the reference range. The patient demographics, diagnosis, medical history and comorbidities, the date and time of K+ levels at most recent K+ level before the transfusions, at the time of hyperkalemia occurred, and follow-up when available were recorded. The types of

treatment for hyperkalemia, creatinine (Cr) level at the closest time of but before the hyperkalemia occurrence, and mortality within 1-day and 7-days after the hyperkalemia occurrence were also collected.

Each RBC unit that was administered within 12 hours prior to hyperkalemia occurrence was reviewed in each patient who had TAH. The storage age, volume of the unit, blood type and modification of the units (leukoreduced, irradiated, washed, supernatant reduced), total volume of RBC transfused within 12 hours, and date and approximate start and end times of transfusion of each unit were also recorded when available. Irradiation of RBC units were performed based on each facility's protocol; universal irradiation of RBC unis for pediatric patients by default in 3 facilities and on request in 1 facility in study period.

Estimated total blood volume (eTBV) in each patient was calculated based on patient age at the time of transfusion as follows: premature infant 100ml/Kg, <1 month old 85 ml/Kg, <4 months old 75 ml/Kg, ≥4 months old male 70 ml/Kg and female 65 ml/Kg. The RBC IR was calculated from volume of RBC transfused and start/end time of transfusion.

Statistical analysis

After completion of the data collection from four facilities, analysis was performed in aggregate. Due to skewed distribution of the investigated patients age (most patients were younger than 5 years old), results in median are mainly used for analysis. The patients are grouped into 4 groups by age (Table 1 and 4), into 2 groups with hyperkalemia occurrence during or after the transfusion (Table 5-A), and into 2 groups with or without 1-day mortality (Table 6). RBC units are also grouped into 2 groups with hyperkalemia occurrence during or after the transfusion for analysis on irradiation effect (Table 5-B).

In addition to basic descriptive analysis, further statistical analyses were performed using R Software (R-Project, R Foundation for statistical computing, version 4.0.0; Vienna, Austria). Results were considered statistically significant when P value was < 0.05. Associations between categorical variables were assessed using Fisher's exact test and Chi-squared test for trend in proportions, as appropriate. The relationship between the death within one-day of hyperkalemia (dependent variable) and other variables (independent variables) collected during the study were assessed using univariate and multivariate binomial regression models. Univariate or multi-variate regression analyses were also performed for predictability of death within one day of hyperkalemia occurrence.

Results

There were 3,777 patients who received 19,649 units of RBC transfusions during the study period in four facilities (Table 1). Hyperkalemia during or within 12 hours after RBC transfusion was found 37 times in 35 patients (0.93% of total number of patients who received RBC transfusions). Two patients had a second TAH event after K+ level on the first TAH was returned to normal. These were investigated and analyzed as two occurrences. Mortality within 1-day after TAH among the patients who developed TAH was 20% (7 patients) overall with highest occurrence in age group 1-5 years old (25.00%, 3 patients in 12 patients who had TAH). Notably, among 3 patients that died within 1-day in <1-year-old group (42.86% of 7 mortalities), two patients were neonates, less than 28 days of age (28.57 % of total 7 mortalities). Between age groups, the number of the patients who had TAH and 1-day mortality after hyperkalemia were not statistically different. The trend of the result in each age group from <1-year-old group to 11-<18 years-old group was also not statistically significant (P for trend: 0.385 and 0.846).

Patients that developed TAH had a median age and weight at the time of transfusion of 1.28 years old (0 - 16.2 years old) and 9.80 kg (0.70 – 45.8 kg) respectively (Table 2). All patients had multiple serious comorbidities; comorbidities which affected more than 20% of patients were prematurity, anemia, and cardiac, respiratory, renal, and liver dysfunctions. All 35 patients had at least 2 comorbidities. The high volume of RBCs was used for priming extracorporeal circuits in 8 patients; ECMO in 6 patients and CPB in 2 patients.

TAH occurred during transfusion in 48.65% of the time (P=0.029, Table 3). Overall 64.86 % (24/37 occurrences) of TAH occurred during or within 30 minutes of transfusion. Hyperkalemia was treated in 51.35 % of occurrences. Two occurrences were not treated because the patients died before the treatment initiated. The details of treatments are fluid bolus, furosemide, albuterol, insulin, calcium gluconate, sodium bicarbonate, stop potassium drip, hook up with continuous renal replacement therapy and combination of those.

A group of 6-10 years-old includes only one patient, therefore, this group does not have a statistical power. Median pre-transfusion Cr was within normal limit (0.20 -6.9 mmol/L) except 6-10 years-old group with one patient and median K+ increase from pre-transfusion K+ level was 1.40 mmol/L (0.4-4.3 mmol/L, Table 4). Median age of the RBC units was 10.0 days old (3-28 days). Times of transfusion start and end were available in 63 units of total 79 transfused units. Age of the units, transfused RBC volume within 12 hours before TAH occurrence (tV-12), IR and IR adjusted by eTBV (IR/eTBV) were statistically different between age groups. Median tV-12 was 24% of eTBV and IR/Kg was 19.57 ml/Kg/hour.

The transfused volume and IR in each patient, and the age and irradiation status of RBC units, with the timing of TAH occurrences were analyzed in 4 groups; TAH during transfusion, TAH after transfusion, data from the specific unit when TAH occurred, and the total occurrences

(Table 5). Table 5-A shows the timing of TAH occurrence with transfusion in cases that IR could be calculated (N=33). The median tV-12/eTBV, IR/Kg and IR/eTBV were higher in TAH occurrences during the transfusion than TAH occurrence after the transfusion (p 0.045, 0.049, and 0.019 respectively). Table 5-B shows the irradiation status and storage age of transfused RBC units in the same groups. The number of ~~irradiation of the~~the irradiated units and median age of the units were slightly higher in the group with TAH occurrences during the transfusion, but the time from irradiation to transfusion was shorter in this group. None of those data were statistically significantly different ($p>0.05$).

A total of 79 RBC units were transfused for 35 patients that experienced TAH. Thirty-four units (43.04%) were AS-1 RBC units and 45 units (56.96%) were AS-3 units. Sixty-three units (79.75%) were blood type O (45 Rh+ and 18 Rh-). Blood type of the units were all compatible with the patients, however, 36 blood type O units were transfused to 17 blood type non-O patients (48.57% of total 35 patients). All units were leukoreduced and 49 units (62.03%) were irradiated (Table 5-B). None of the units were either washed or plasma reduced.

Mortality occurred in 7 patients within 1-day of hyperkalemia occurrence with multiple comorbidities; 3 of them had prematurity and 3 of them had kidney dysfunction. The details of those 7 patients (Pt 1-7) were compared with other 28 patients who survived at least 1-day after TAH event and total of 35 patients who had TAH (Table 6). Pt 3 had 2 episodes of TAH, therefore, 2 data points were divided by a slash (/). Five patients (71.43%) died during the transfusion and two patients died before the initiation of treatment. Comparing data between groups of these 7 patients and other 28 patients, the median IR, IR/Kg, IR/Kg/hour and the prevalence of TAH event during the transfusion were all higher in 7 patient group, however, the differences were not statistically significant. Overall, none of the collected variables were

predictive of 1-day mortality after hyperkalemia occurrence in univariate or multivariate analysis regression analysis (all p>0.05).

Discussion

Although cases of TAH have been reported and the occurrence of TAH has been recognized ~~and previously reported~~ for quite some time, especially in pediatric anesthesiology[21], the prevalence is low. ~~and a~~Available literature is mainly case reports or case series from one facility. Our study is the first multi-center systematic review in a large cohort of pediatric population.

In previous reports of TAH, many patients were pediatric patients especially neonates[9-14], however, quite a number of the literatures reported adult patients who developed TAH[14-18]. Our study also shows that the age group of 1-5 years-old had the biggest prevalence of TAH but 7 patients were in the age group of 11-<18 years-old some of whom had an adult body size. Therefore, TAH may occur not only in the patients with a smaller body size as we expected but also in the patients with an adult body size. However, the median age of the patients with TAH was 1.28 years-old and the median body weight was 9.80 Kg, and 27 of 35 patients (77.14%) that had TAH were ≤5 years old (0-5.6 years old), which may still suggest that the patients with smaller body size rather than bigger size are at higher risk for TAH in pediatric population. In addition, of the 7 patients that died within 1-day after the TAH episode, six patients (85.71%) were ≤5 years old. Among them, two patients (28.6%) were neonates (≤28 days old), which is ~~noticeably~~ high and consistent with majority of published cases reporting cardiac arrest due to TAH occurring in neonates.[9,10,12]

Our study found that all patients that had TAH had multiple comorbidities. Understandably, the comorbidity with highest frequency was history of kidney dysfunction,

although the laboratory data (Cr) does not suggest most of these patients were in renal failure before the TAH episode. However, considering lower reference rage of Cr for patients ≤4 years old (0.2-0.6 mg/dL), 5 of 7 patients with 1-day mortality had slightly higher pre-transfusion Cr level above this reference range, which suggests they might have a lower K+ excretion. Prematurity, blood loss/iron deficiency anemia, and cardiac/respiratory/liver dysfunctions were also commonly seen in patients with TAH.

We also investigated the role of RBC volume on the prevalence of TAH. Small volume of RBC transfusion in the normal IR (generally 10-15 mL/Kg) is reported not to cause TAH, but massive transfusion is often linked to TAH occurrence.[10,11,22] Brown et al.[22] reported 10 of 11 pediatric patients who underwent massive blood transfusion in craniofacial surgery had an increase in K concentration. Vohra et al.[23] reported that smaller patients (<5Kg) who underwent cardiac surgery with CPB experienced hyperkalemia but larger patients did not. On the other hand in adult patients, Carmichael et al.[24] reported 47% of the adult patients had post-operative hypokalemia, not hyperkalemia, after transfusion of more than 10 RBC units. The reason of hypokalemia is thought to be an intake of K+ by K+ depleted RBCs with restored Na-K-ATPase pump, but hypokalemia is not reported in pediatric population. Therefore, the risk of TAH from high volume of transfusion may be specific for ~~patients with~~ young patients with smaller body size who have low TBV and immature kidneys which may cause low K+ excretion. Our data showed mean transfused RBC volume within 12 hours before hyperkalemia occurrence was only 24% of eTBV. However, we found that a high volume of RBC transfusion for priming of ECMO and CPB devises was associated with TAH. In addition, the patients on ECMO or CPB who had TAH during the transfusion were ≤5 years old (1 day – 5.6 years old) with median weight of 7.58 Kg (2.57-21.7Kg). Our results may support previous accounts and the massive

RBC transfusion may be a higher risk to cause TAH in smaller patients. Also, the patients who developed hyperkalemia during transfusion received larger amounts of transfusions adjusted by eTBV than patients who developed hyperkalemia after transfusion. These data may suggest that higher transfusion volume may be also ~~at least~~ contributing to TAH occurrence during the transfusion.

Rapid transfusion is also often linked to TAH occurrence.[2,16,17] In addition to the fact that hyperkalemia causes suppression of electrical activity, Brown et al.[2] reported that rapid RBC transfusion might depress cardiac output due to ineffective cardiac contraction resulting in an acute increase in the K+ concentration in hypovolemic children (10-15 Kg). They also reported higher K+ levels were found in those children with rapid blood transfusion than children without rapid transfusion at the time of cardiac arrest. Our patients did not receive high volume of RBCs but received transfusion in much higher IR than the safe transfusion threshold of 15 ml/Kg/5 hours (3 ml/Kg/hour) that Strauss[5] stated. Our study also shows the age group of 1-5 years-old that had the highest prevalence in 4 age groups had the highest median IR and 1-day mortality rate after the TAH episode. Among the patients with 1-day mortality, IR greater than 3 ml/Kg/hour was found in 6 of 8 TAH occurrences (75.0%), while one patient had routine IR at the time of death and another with no data available. Moreover, our study shows significantly higher IR adjusted by patient weight and eTBV in the TAH occurrences during the transfusion than those after the transfusion. These results may suggest IR may be an important factor to predict TAH occurrence.

Strikingly, most of the patients in this study with TAH received *fresher* RBC units (3-28 days) and the median age of the units transfused was only 10 days, which should not contain extremely high K+. Irradiation was performed in 62% of total transfused units in 35 patients,

however, the number of irradiated units and time from irradiation to transfusion did not reveal statistically significant differences between units of TAH occurrence during the transfusion and after the transfusion. These results may imply the features of the units might not be as influential as we originally expected.

There are several limitations for this study. First, the start and end time of each RBC transfusion may not be precise in some cases because those times were manually entered in most facilities and in some cases only time of issue from blood bank and general time of use during surgery/massive transfusion were captured. Therefore, the IR might not be perfectly accurate. Second, it was difficult to assess if the transfusion caused hyperkalemia and if TAH is the cause of mortality because all patients had multiple comorbidities. The need for the rapid and large volume of RBC transfusion suggests the patient had medical or surgical issues unrelated to transfusion that could have caused their demise. Third, the control group (patients who received RBC transfusion but did not develop hyperkalemia) necessary to analyze multi-variate analysis for prediction of risk factors for TAH occurrence was not investigated at this time. Therefore, multi-variate analysis for risk factors could not be performed. Four, since this study is retrospective study, K+ concentration of each RBC units were not available. Therefore, the direct correlation between K+ level of the RBC unit and post-transfusion serum K+ level or TAH occurrence could not be analyzed.

Conclusions

The overall prevalence of TAH in pediatric population is 0.93%, which means one in 108 patients may experience TAH with RBC transfusions. The 1-day mortality after TAH is high (20%) in such patients. Causes of TAH are multi-factorial and all affected patients in our study

had multiple comorbidities that could potentiate TAH and its associated complications. Our data shows TAH can occur with RBC transfusion of only 24% of patient eTBV within 12 hours, but median IR/weight was 19.57ml/Kg/hour. Also the highest prevalence of TAH occurrence and 1-day mortality were found in 1-5 years-old group with highest median IR in four age groups. High transfusion volume may not necessarily cause TAH, however, it may be a higher risk for TAH in small patients. Higher IR may be an important factor to predict TAH occurrence especially during the transfusion. Importantly, the irradiation status and storage age of RBC units may not be as influential as expected. The study demonstrates the scope and importance of TAH in pediatric population. Knowledge and mitigation of the identified risk factors for TAH are critical to prevent adverse consequences.

References

1. Vraets A, Lin Y, Callum JL. Transfusion-associated hyperkalemia. Transfus Med Rev 2011;**25**: 184-96.
2. Brown KA, Bissonnette B, McIntyre B. Hyperkalaemia during rapid blood transfusion and hypovolaemic cardiac arrest in children. Can J Anaesth 1990;**37**: 747-54.
3. Lockwood WB, Leonard J, Liles SL. Storage, monitoring, pretransfusion processing, and distribution of blood components. In: Roback JD, Combs MR, Grossman BJ, Hillyer CD, editors. Technical Manual. 16th ed. Bethesda, MD: AABB; 2008. p289.
4. Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999;**39**: 128-34.
5. Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. Transfusion 2000;**40**: 1528-40.
6. Liu EA, Mannino FL, Lane TA. Prospective, randomized trial of the safety and efficacy of a limited donor exposure transfusion program for premature neonates. J Pediatr 1994;**125**: 92-6.
7. Lee DA, Slagle TA, Jackson TM, Evans CS. Reducing blood donor exposures in low birth weight infants by the use of older, unwashed packed red blood cells. J Pediatr 1995;**126**: 280-6.
8. Strauss RG, Burmeister LF, Johnson K, James T, Miller J, Cordle DG, Bell EF, Ludwig GA. AS-1 red cells for neonatal transfusions: a randomized trial assessing donor exposure and safety. Transfusion 1996;**36**: 873-8.

9. Hall TL, Barnes A, Miller JR, Bethencourt DM, Nestor L. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfusion 1993;**33**: 606-9.

10. Chen CH, Hong CL, Kau YC, Lee HL, Chen CK, Shyr MH. Fatal hyperkalemia during rapid and massive blood transfusion in a child undergoing hip surgery--a case report. Acta Anaesthesiol Sin 1999;**37**: 163-6.

11. Buntain SG, Pabari M. Massive transfusion and hyperkalaemic cardiac arrest in craniofacial surgery in a child. Anaesth Intensive Care 1999;**27**: 530-3.

12. Baz EM, Kanazi GE, Mahfouz RA, Obeid MY. An unusual case of hyperkalaemia-induced cardiac arrest in a paediatric patient during transfusion of a 'fresh' 6-day-old blood unit. Transfus Med 2002;**12**: 383-6.

13. Woodforth IJ. Resuscitation from transfusion-associated hyperkalaemic ventricular fibrillation. Anaesth Intensive Care 2007;**35**: 110-3.

14. Smith HM, Farrow SJ, Ackerman JD, Stubbs JR, Sprung J. Cardiac arrests associated with hyperkalemia during red blood cell transfusion: a case series. Anesth Analg 2008;**106**: 1062-9, table of contents.

15. Stoops CM. Acute hyperkalemia associated with massive blood replacement. Anesth Analg 1983;**62**: 1044.

16. Carvalho B, Quiney NF. 'Near-miss' hyperkalaemic cardiac arrest associated with rapid blood transfusion. Anaesthesia 1999;**54**: 1094-6.

17. Tsukamoto S, Maruyama K, Nakagawa H, Iwase Y, Kitamura A, Hayashida M. Fatal hyperkalemia due to rapid red cell transfusion in a critically ill patient. J Nippon Med Sch 2009;**76**: 258-64.

18. Rizos CV, Milionis HJ, Elisaf MS. Severe hyperkalemia following blood transfusions: Is there a link? World J Nephrol 2017;**6**: 53-6.

19. Strauss RG. RBC storage and avoiding hyperkalemia from transfusions to neonates & infants. Transfusion 2010;**50**: 1862-5.

20. Fung MK, Roseff SD, Vermoch KL. Blood component preferences of transfusion services supporting infant transfusions: a University HealthSystem Consortium benchmarking study. Transfusion 2010;**50**: 1921-5.

21. Bhananker SM, Ramamoorthy C, Geiduschek JM, Posner KL, Domino KB, Haberkern CM, Campos JS, Morray JP. Anesthesia-related cardiac arrest in children: update from the Pediatric Perioperative Cardiac Arrest Registry. Anesth Analg 2007;**105**: 344-50.

22. Brown KA, Bissonnette B, MacDonald M, Poon AO. Hyperkalaemia during massive blood transfusion in paediatric craniofacial surgery. Can J Anaesth 1990;**37**: 401-8.

23. Vohra HA, Adluri K, Willets R, Horsburgh A, Barron DJ, Brawn WJ. Changes in potassium concentration and haematocrit associated with cardiopulmonary bypass in paediatric cardiac surgery. Perfusion 2007;**22**: 87-92.

24. Carmichael D, Hosty T, Kastl D, Beckman D. Hypokalemia and massive transfusion. South Med J 1984;**77**: 315-7.

Table 1: Number of transfused RBC units and patients by patient age in four facilities

Patient age (years old)	<1	1 - 5	6 - 10	11 - <18	Total
NO of RBC units transfused	7,467	3,620	3,139	5,423	19,649
NO of patients who received RBC	1,523	892	553	809	3,777
NO of patients who had hyperkalemia	15 (0.98%)	12 (1.35%)	1 (0.18%)	7 (0.87%)	35 (0.93%)
P	0.876	0.265	0.079	1.00	
P for trend	0.385				
Mortality within 1 day of hyperkalemia	3 (20.00%)	3 (25.00)	0 (0%)	1 (14.29%)	7 (20.00%)
P	1.00	0.713	N/A	1.00	
P for trend	0.846				

Table 2: Demographics, comorbidities and features of transfusion in 35 patients who had hyperkalemia episode(s) and

			N (%) or results
Gender	Female		20 (57.14)
	Male		15 (42.86)
Race	Caucasian		13 (37.14)
	African American		6 (17.14)
	Hispanic		1 (2.86)
	Asian		1(2.86)
	Other/non-Hispanic/Unknown		14 (40.00)
Median	Age		1.28 years old
	Weight		9.80 kg
	Estimated total blood volume		637.00 mL
Comorbidities	Prematurity		**10 (28.57)**
	Cardiac dysfunction		**10 (28.57)**
	Congestive heart failure		4 (11.43)
	Cardiac arrhythmias		4 (11.43)
	Respiratory dysfunction		**10 (28.57)**
	Kidney dysfunction		**17 (48.57)**
	Liver dysfunction		**8 (22.86)**
	Intracranial disorders/surgery		4 (11.43)
	Orthopedic surgery		1 (2.86)
	Blood loss/Iron deficiency anemia		**10 (28.57)**
	Sepsis		4 (11.43)
	Dialysis		3 (8.57)
Priming of life support when hyperkalemia occurred		ECMO	6 (17.14)
		CPB	2 (5.71)
Types of Access		Central line	7 (20.00)
		Peripheral veins	8 (22.86)
		Unknown	20 (57.14)
Mortality after hyperkalemia occurrence		In 1 day	7 (20.00)
		In 2-7 days	4 (11.43)
		Within 7 days	11 (31.43)

ECMO: extracorporeal membrane oxygenation, CPB: cardiopulmonary bypass

Table 3: The features of hyperkalemia in 37 occurrences in 35 patients

		N (%)	P	P for trend
Timing of hyperkalemia (K+>1.4mmol/L from previous normal)	During	18 (48.65)	**0.029**	**<0.001**
	≤ 30 mins	6 (16.22)	0.810	
	30 mins to 1 hr	3 (8.11)	0.197	
	1 hr to 6 hrs	8 (21.62)	0.821	
	6 hrs to 12 hrs	2 (5.41)	0.107	
	Total	37 (100)		
Any treatments performed for hyperkalemia	Yes	19 (51.35)	0.87	
	No	18 (48.65)		

min: minute, hr: hour

Table 4: Patients and RBC units on transfusions

		Age groups of the patients				Total	P or P for trend (*)
		< 1 yo	**1-5 yo**	**6-10 yo**	**11-<18 yo**		
Patients (N or median)	Patients (N)	15	12	1	7	35	
	Weight (kg)	3.03	11.70	28.00	48.46	9.80	
	Creatinine (mg/dL)	0.86	0.39	1.50	0.70	1.01	0.149
	K+ increase (mmol/L)	0.70	1.65	2.00	1.40	1.40	0.119
	Hyperkalemia occurrences (N)	17	12	1	7	37	**0.001***
RBC units and Transfusion (N or median)	Units transfused (N)	25	29	1	24	79	0.072*
	Units with transfusion time available (N)	21	22	1	19	63	
	Age of units (days)	5.00	11.00	6.00	14.00	10.00	**0.021**
	tV-12 (ml)	51.00	263.00	280.00	750.00	250.00	**<0.01**
	tV-12 / eTBV	0.26	0.25	0.15	0.24	0.24	0.710
	IR (ml/hour)	40.00	1050.00	227.03	819.00	191.25	**<0.001**
	IR/weight (ml/Kg/hour)	16.56	50.92	8.11	23.81	19.57	0.414
	IR/eTBV (/hour)	0.22	1.33	0.12	0.35	0.29	**0.021**

yo: years old
Creatinine: creatinine closest of but before hyperkalemia occurrence (mg/dL)
K+ increase: median increase of K level at the time of hyperkalemia from previous K+ level
tV-12: transfused RBC volume within 12 hours before hyperkalemia occurrence
eTBV: estimated total blood volume
IR: infusion rate

Table 5: Comparison of timing of TAH occurrence: during transfusion and after transfusion (data represents median)

A: Infusion rate and hyperkalemia occurrence in cases infusion rate could be calculated

	Hyperkalemia occurrence during transfusion (N=14)	Hyperkalemia occurrence after transfusion (N=19)	P	On specific RBC unit when TAH occurred (N=14)	Hyperkalemia Occurrences with available infusion rate (N=33)
tV-12 (ml)	255	176	0.716		215
tV-12/eTBV	0.56	0.17	**0.045**		0.24
IR (ml/hour)	474.00	100.87	0.176	96.69	127.27
IR/weight (ml/Kg/hour)	30.24	8.48	**0.049**	26.18	22.11
IR/eTBV (/hour)	0.39	0.11	**0.019**	0.34	0.33

TAH: transfusion associated hyperkalemia
tV-12: transfused RBC volume within 12 hours of hyperkalemia occurrence
eTBV: estimated total blood volume of the patient
IR (Infusion rate)

B: Effects of irradiated units

	Units when hyperkalemia occurred during transfusion (N=46)	Units when hyperkalemia occurred after transfusion (N=33)	P	Specific unit at the time of hyperkalemia (n=14)	Total number of units (N=79)
Irradiated units (% in each group's total)	30 (65.22)	19 (57.58)	0.620	11 (78.57)	49 (62.03)
Age of the units (day)	12.00	9.00	0.253	7.00	10.00
Time from irradiation to transfusion (min)	87.00	147.00	0.666	87.00	

Table 6: Comparison of individual data of patients with mortality within 1 day after hyperkalemia and others (for analytical numbers represent median)

		Pt 1	Pt 2	Pt 3	Pt 4	Pt 5	Pt 6	Pt 7	Pts with 1-day mortality (N=7)	Pts without 1-day mortality (N=28)	P	Total (N=35)
Patient	Age (year old)	1 day	5 day	39 days	2.1	2.2	3.3	13.0	2.12	1.27	0.808	1.28
	Weight (kg)	2.8	0.68	1.03	10.40	12.39	9.80	25.0	9.80	9.90	0.257	9.80
	eTBV (ml)	280	68.0	103.0	676.0	805.6	637.00	1625.0	637.0	643.50	0.375	637.0
	Creatinine (mmol/L)	1.4	0.93	1.6	0.9	0.2	0.63	0.2	0.9	0.7	0.951	1.01
	K+ increase	0.4	0.9	0.6/1.1	2.6	1.8	1.9	4.3	1.45	1.40	0.577	1.40
RBC units	Age of unit(s)	9.0	4.0	4.5	9	24.0	16	17.0	9.0	10.0	0.622	10.0
	tV-12 (ml)	60.0	38.0	15.0/9.0	250.0	176.0	530.0	1566.0	118	276.0	0.549	250.0
	tV-12/eTBV	0.21	0.56	0.15/0.09	0.37	0.22	0.83	0.96	0.29	0.24	0.349	0.24
	IR (ml/hour)	55.38	NA	3.81/2.77	2100.00	54.43	67.13	756.00	917.50	105.88	0.343	191.25
	IR/weight (ml/Kg/hour)	19.78	NA	3.70/2.69	201.92	4.39	6.85	30.24	36.70	14.75	0.360	19.57
	IR/eTBV (/hour)	0.20	NA	0.04/0.03	3.11	0.07	0.11	0.47	0.56	0.21	0.083	0.29
Timing of hyperkalemia recorded during or after the transfusion		120 min	during	10 min/ during	during	30 min	during	during	during 5 (71.43%)	during 12 (42.86%)	0.352	
Treatment for hyperkalemia		1, 2	2, 3, 4	1, 2, 5 / N	1, 2	6	N	1, 2, 3				
Main comorbidities		Prem. DIC Seizure	Prem. Sepsis C/P-d	Prem. K-d	ECMO Trisomy C/L-d	K-d CRRT	Sepsis K-d R-d	Encephalopathy R-d Ventilator				

Pt: patient
Creatinine: creatinine before hyperkalemia occurrence (mg/dL)
tV-12 (ml): transfused RBC volume within 12 hours before hyperkalemia occurrence
eTBV (ml): estimated total blood volume
IR: Infusion rate
min: minute
Treatment: 1. Sodium Bicarbonate, 2. Calcium, 3. Insulin, 4. Albuterol, 5. Fluid, 6. Continuous renal replacement therapy, N: none
Comorbidities: Prem.: prematurity, DIC: disseminated intravenous coagulopathy, ECMO: extracorporeal membrane oxygenation
C, L, K, R-d: Cardiac-, Liver-, Kidney-, Respiratory dysfunction, CRRT: continuous renal replacement therapy